SG11201804884PA - Method for modulating autophagy and applications thereof - Google Patents
Method for modulating autophagy and applications thereofInfo
- Publication number
- SG11201804884PA SG11201804884PA SG11201804884PA SG11201804884PA SG11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA
- Authority
- SG
- Singapore
- Prior art keywords
- autophagy
- jakkur
- centre
- bangalore
- lab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 0101101HEIM1100 1111111110111011# International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/098467 Al 15 June 2017(15.06.2017) WIPO I PCT (51) International Patent Classification: Aravinda; Autophagy lab, Molecular Biology and Genet- A61K 31/277 (2006.01) A61K 31/443 (2006.01) ics Unit, Jawaharlal Nehru Centre for Advanced Scientific A61K 31/325 (2006.01) A61P 25/00 (2006.01) Research, Jakkur, Bangalore 560064 (IN). A61K 31/352 (2006.01) A61P 25/28 (2006.01) A61K 31/4025 (2006.01) A61P 25/16 (2006.01) (74) Agents: MUKHARYA, Durgesh et al.; K&S Partners, 4121/B, 6th Cross, 19A Main, HAL II Stage (Extension), (21) International Application Number: Bangalore Karnataka 560 038 (IN). PCT/IB2016/057498 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: 9 December 2016 (09.12.2016) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: 6596/CHE/2015 9 December 2015 (09.12.2015) IN MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicant: JAWAHARLAL NEHRU CENTRE FOR RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. ADVANCED SCIENTIFIC RESEARCH [IN/IN]; Jakkur, Karnataka, Bangalore 560064 (IN). (84) Designated States (unless otherwise indicated, for every (72) Inventors: MANJITHAYA, Ravi; Autophagy lab, Mo- _ lecular Biology and Genetics Unit, Jawaharlal Nehru kind of regional protection available): ARIPO (BW, GH, Centre for Advanced Scientific Research, Jakkur, Ban- galore 560064 (IN). MISHRA, Piyush; Autophagy lab, Molecular Biology and Genetics Unit, Jawaharlal Nehru GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, — _ _ Centre for Advanced Scientific Research, Jakkur, Ban- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: = galore 560064 (IN). SANTHI NATESAN, Suresh; Auto- phagy lab, Molecular Biology and Genetics Unit, Jawa- harlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064 (IN). BATS, Somya; Auto- = = lab, Molecular Biology and Genetics Unit, Jawa- phagy harlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064 (IN). AMMANATHAN, of inventorship (Rule 4.17(iv)) Published: Veena; Autophagy lab, Molecular Biology and Genetics = Unit, Jawaharlal Nehru Centre for Advanced Scientific Re- with international search report (Art. 21(3)) = search, Jakkur, Bangalore 560064 (IN). CHAVALMANE, = = = = = = 1-1 IN 7r GC t:t © IN 1-1 (54) Title: METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF 0 ei (57) : The present disclosure relates to method of modulating autophagy by modulators of autophagy, wherein the auto - en. ) phagy includes but is not limited to macroautophagy, chaperone mediated autophagy and microautophagy. The present disclosure further relates to modulators of autophagy for increasing or decreasing the autophagic flux. The disclosure also relates to modulator per se in modulating autophagy including but not limiting to macroautophagy, chaperon mediated autophagy and microautophagy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN6596CH2015 | 2015-12-09 | ||
PCT/IB2016/057498 WO2017098467A1 (en) | 2015-12-09 | 2016-12-09 | Method for modulating autophagy and applications thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804884PA true SG11201804884PA (en) | 2018-07-30 |
Family
ID=57681685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804884PA SG11201804884PA (en) | 2015-12-09 | 2016-12-09 | Method for modulating autophagy and applications thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180369186A1 (en) |
EP (1) | EP3386498A1 (en) |
AU (2) | AU2016366810A1 (en) |
SG (1) | SG11201804884PA (en) |
WO (1) | WO2017098467A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109384782A (en) * | 2017-08-04 | 2019-02-26 | 厦门大学 | Substituted five-membered and hexa-member heterocycle class compound, preparation method, pharmaceutical composition and application thereof |
JOP20180094A1 (en) * | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | Heterocyclic compound as a protein kinase inhibito |
US11801284B2 (en) | 2017-12-13 | 2023-10-31 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
WO2019194939A1 (en) * | 2018-04-02 | 2019-10-10 | The Children's Medical Center Corporation | Methods and compositions relating to the inhibition of ip6k1 |
CN110812348A (en) * | 2018-08-13 | 2020-02-21 | 天津科技大学 | Novel application of quaternary ammonium compound |
US20240226063A1 (en) * | 2021-04-29 | 2024-07-11 | Jawaharlal Nehru Centre For Advanced Scientific Research | Soluble analogues of 6bio thereof and implementation thereof |
EP4183449A1 (en) * | 2021-11-17 | 2023-05-24 | Samsara Therapeutics Inc. | Autophagy inducing compounds and uses thereof |
WO2024199341A1 (en) * | 2023-03-30 | 2024-10-03 | 浙江海正药业股份有限公司 | Fused polycyclic derivative and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146879A2 (en) * | 2010-05-20 | 2011-11-24 | University Of Rochester | Methods and compositions related to modulating autophagy |
-
2016
- 2016-12-09 SG SG11201804884PA patent/SG11201804884PA/en unknown
- 2016-12-09 AU AU2016366810A patent/AU2016366810A1/en not_active Abandoned
- 2016-12-09 EP EP16820017.8A patent/EP3386498A1/en not_active Withdrawn
- 2016-12-09 US US16/060,445 patent/US20180369186A1/en not_active Abandoned
- 2016-12-09 WO PCT/IB2016/057498 patent/WO2017098467A1/en active Application Filing
-
2019
- 2019-12-04 AU AU2019275604A patent/AU2019275604A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2016366810A1 (en) | 2018-06-28 |
AU2019275604A1 (en) | 2020-01-02 |
WO2017098467A1 (en) | 2017-06-15 |
US20180369186A1 (en) | 2018-12-27 |
EP3386498A1 (en) | 2018-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804884PA (en) | Method for modulating autophagy and applications thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201804694SA (en) | Dual controls for therapeutic cell activation or elimination | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201808598UA (en) | Detecting microbial infection in wounds | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201806853VA (en) | Abstracted graphs from social relationship graph | |
SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201805898RA (en) | Liquid composition comprising a multistage polymer, its method of preparation and its use | |
SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201804867RA (en) | Coating compositions and treating method | |
SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201804587QA (en) | Isoindole compounds |